Sign in

CELC on Nasdaq

Celcuity Inc.

Celcuity Inc. is an American medical laboratories services company based in Minneapolis.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerCELC on Nasdaq2
  • IndustryServices-Medical Laboratories2
  • HeadquartersMinneapolis, United States2
  • Incorporated inDE3
  • Business address16305 36Th Avenue N, Suite 100, Minneapolis, Mn 554463
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI25490070W7UU7W2SEY872
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 65442842

See how the biggest companies compare on our leaderboards

States in 2025, and approximately 42,170 breast cancer patients would die of the disease.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income5678910-$172.2M in 2025+2106% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$7.8M-$7.8M20192020: -$9.6M-$9.6M2020+22%2021: -$28.4M-$28.4M2021+197%2022: -$39.4M-$39.4M2022+39%2023: -$66.2M-$66.2M2023+68%2024: -$113.3M-$113.3M2024+71%2025: -$172.2M-$172.2M2025+52%
Net income5678910-$177.0M in 2025+2306% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$7.4M-$7.4M20192020: -$9.5M-$9.5M2020+29%2021: -$29.6M-$29.6M2021+212%2022: -$40.4M-$40.4M2022+36%2023: -$63.8M-$63.8M2023+58%2024: -$111.8M-$111.8M2024+75%2025: -$177.0M-$177.0M2025+58%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$145.0M$104.2M
General and administrative$27.2M$9.1M
Total operating expenses$172.2M$113.3M
Loss from operations-$172.2M-$113.3M
Interest expense-$17.1M-$10.3M
Interest income$12.3M$11.8M
Other (expense) income, net-$4.8M$1.5M
Net loss before income taxes-$177.0M-$111.8M
Net loss-$177.0M-$111.8M
Net loss per share, basic-$3.79-$2.83
Net loss per share, diluted-$3.79-$2.83
Weighted average common shares outstanding, basic46.8M shares39.4M shares
Weighted average common shares outstanding, diluted46.8M shares39.4M shares

Compare Celcuity Inc. with another company

Corporate structure

Celcuity Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Celcuity Inc.

  • Celcuity Inc. Minneapolis, Minnesota, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Celcuity Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Computer equipment and software$100.0K10 Dec 31, 2025$010 Dec 31, 2024
Property and equipment, before depreciation$2.7M10 Dec 31, 2025$2.3M10 Dec 31, 2024+14.2%
Accumulated depreciation$2.2M10 Dec 31, 2025$2.0M10 Dec 31, 2024+8.4%
Property and equipment, net$499.0K10 Dec 31, 2025$336.0K10 Dec 31, 2024+48.5%
Operating-lease assets (leased space)$51.0K10 Dec 31, 2025$216.0K10 Dec 31, 2024−76.4%

Real estate and locations

ItemLatestA year beforeChange
Area of land19,594 sq ft10 Nov 30, 2025

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$165.7M10 Dec 31, 2025$22.5M10 Dec 31, 2024+636.0%
Marketable securities, current$275.8M10 Dec 31, 2025$212.6M10 Dec 31, 2024+29.7%
Debt securities held to maturity$275.8M10 Dec 31, 2025$212.6M10 Dec 31, 2024+29.7%

Properties, in its own words

We currently lease and occupy approximately 16,000 square feet in Minneapolis, Minnesota, which includes our clinical laboratory and offices. On March 13, 2023, we signed the fourth amendment to our lease agreement, which expires April 30, 2026. The lease provides for monthly rent, real estate taxes and operating expenses. We believe that this leased space is adequate to meet current requirements.

On November 5, 2025, we signed a lease agreement for new clinical laboratory and office space in Minneapolis, Minnesota for approximately 19,594 square feet. The lease term will commence on April 1, 2026. The lease provides for monthly rent, real estate taxes and operating expenses. The lease term is 62 months with two options to extend the lease term for five years each.

Item 2 of the 10-K filed Mar 26, 2026.4

Leadership

Who has led Celcuity Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Vicky Hahne2017–now
20202025
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, Director, PromoterBrian F. Sullivan named May 26, 2022 to Sep 23, 202522

Former names

  • Celcuity LLCMar 24, 2014 to Sep 15, 20173

Timeline

  1. Oct 2, 20268-K Executive or director change; Regulation FD disclosure23
  2. Sep 30, 20268-K Regulation FD disclosure; Other events24
  3. Aug 26, 20268-K Regulation FD disclosure; Other events25
  4. Aug 13, 20268-K Results of operations26
  5. Jul 15, 20268-K Regulation FD disclosure; Other events27
  6. Jul 15, 20268-K Regulation FD disclosure; Other events28
  7. Jun 8, 20268-K Entered a material agreement; Ended a material agreement; New debt or obligation29
  8. Jun 2, 20268-K Regulation FD disclosure; Other events30
  9. May 20, 20268-K Executive or director change31
  10. May 18, 20268-K Executive or director change; Shareholder vote32
  11. May 14, 20268-K Results of operations33
  12. May 1, 20268-K Regulation FD disclosure; Other events34
  13. Sep 15, 2017Founded Celcuity Inc. is founded2

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.92) a share, on Nov 12, 2025.35

When it reported results

  1. Aug 13, 2026Reported quarterly or annual results26
  2. May 14, 2026Reported quarterly or annual results33
  3. Mar 25, 2026Reported quarterly or annual results36
  4. Nov 12, 2025Reported quarterly or annual results37
  5. Aug 14, 2025Reported quarterly or annual results38
  6. May 14, 2025Reported quarterly or annual results39
  7. Mar 31, 2025Reported quarterly or annual results40
  8. Nov 14, 2024Reported quarterly or annual results41

Drug trials and FDA: recently

  1. Jul 14, 2026FDA approval FDA approved Revtorpyk (gedatolisib), a new molecular entity, priority review (NDA 219908).42

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

359 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 62 major events, 128 insider forms, 54 large holders, 14 private raises, 80 other. The latest 20:

  1. Oct 9, 20264 EDGAR
  2. Oct 5, 20264 EDGAR
  3. Oct 5, 20263 EDGAR
  4. Oct 2, 20268-K EDGAR
  5. Sep 30, 20268-K EDGAR
  6. Aug 26, 20268-K EDGAR
  7. Aug 18, 20264 EDGAR
  8. Aug 18, 20264 EDGAR
  9. Aug 18, 20264 EDGAR
  10. Aug 13, 202610-Q EDGAR
  11. Aug 13, 20268-K EDGAR
  12. Aug 11, 2026SCHEDULE 13G EDGAR
  13. Jul 16, 20264 EDGAR
  14. Jul 16, 2026SCHEDULE 13G EDGAR
  15. Jul 16, 2026SCHEDULE 13D/A EDGAR
  16. Jul 15, 20268-K/A EDGAR
  17. Jul 15, 20268-K EDGAR
  18. Jul 14, 2026144 EDGAR
  19. Jul 14, 2026144 EDGAR
  20. Jun 12, 20264 EDGAR

The 359 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

49 open-market trades by officers, directors and large owners since October 2021: 6 buys and 43 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 14, 2026BAKER JULIANSale3,100,000$102.50$317.8MForm 4
May 4, 2026Buller Richard EDirectorSale9,000$140.47$1.3MForm 4
May 4, 2026Dalvey DavidDirectorSale25,000$140.68$3.5MForm 4
Mar 31, 2026Buller Richard EDirectorSale3,000$110.27$330.8KForm 4
Jan 27, 2026Dalvey DavidDirectorSale20,000$120.03$2.4MForm 4
Dec 5, 2025Buller Richard EDirectorSale3,000$105.69$317.1KForm 4
Dec 1, 2025Buller Richard EDirectorSale1,100$98.13$107.9KForm 4
Nov 21, 2025Dalvey DavidDirectorSale15,000$100.00$1.5MForm 4
Nov 20, 2025Buller Richard EDirectorSale3,900$96.73$377.2KForm 4
Sep 8, 2025Baker Bros. Advisors (GP) LLCBuy170,100$56.27$9.6MForm 4
Jul 28, 2025Dalvey DavidDirectorSale109,325$44.08$4.8MForm 4
Oct 23, 2024Buller Richard EDirectorSale350$16.25$5.7KForm 4
Aug 23, 2024Buller Richard EDirectorSale350$16.95$5.9KForm 4
Jun 21, 2024Buller Richard EDirectorSale350$15.68$5.5KForm 4
Apr 24, 2024Buller Richard EDirectorSale350$17.06$6.0KForm 4
Feb 21, 2024Buller Richard EDirectorSale350$14.15$5.0KForm 4
Dec 20, 2023Buller Richard EDirectorSale350$14.37$5.0KForm 4
Dec 15, 2023Dalvey DavidDirectorSale2,940$14.57$42.8KForm 4
Dec 14, 2023Dalvey DavidDirectorSale5,000$14.75$73.8KForm 4
Dec 13, 2023Dalvey DavidDirectorSale5,000$14.50$72.5KForm 4

All 49 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Brian F. Sullivan64$577.1K$16.4M60
2025Lance G. Laing64$472.6K$4.2M60
2025Vicky Hahne59$419.6K$3.4M60
2024Chairman and Chief Executive Officer$525.0K$6.6M60
2024Chief Science Officer$351.5K$1.7M60
2024Chief Financial Officer$267.5K$1.4M60

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$288.5M 2017–2023
Money received by yearMoney received by year, 2017–2023: $288.5M in all. Private raises (Form D) $288.5M.$0$50M$100M$150M2017 · Private raises (Form D): $8.5M201720192021 · Private raises (Form D): $130.0M20212022 · Private raises (Form D): $100.0M2023 · Private raises (Form D): $50.0M2023
Figures by year
YearPrivate raises (Form D)Total
2023$50.0M$50.0M
2022$100.0M$100.0M
2021$130.0M$130.0M
2017$8.5M$8.5M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Oct 20, 2023Raised $50 million in a private offering of securities61 Form D: 2 investors so far Form D
  2. May 15, 2022Raised $100 million in a private offering of equity62 Form D: $156 million offered in all Form D
  3. Apr 8, 2021Raised $130 million in a private offering of debt22 Form D: $352.7 million offered in all Form D
  4. May 5, 2017Raised $2.6 million in a private offering of securities63 Form D: $3 million offered in all Form D
  5. Apr 28, 2017Raised $5.9 million in a private offering of securities64 Form D: $6.6 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Baker Bros. Advisors LP7,915,792$828.2M4.2%No change
Avoro Capital Advisors LLC3,400,000$355.7M3.2%+25,000
Rtw Investments, LP3,304,903$345.8M3.0%+265,282
Perceptive Advisors LLC3,197,200$334.5M5.2%+70,000
BlackRock, Inc.3,018,785$315.8M0.0%+307,253
State Street Corp1,955,304$204.6M0.0%+436,599
Vanguard Capital Management LLC1,874,137$196.1M0.0%+91,243
NEA Management Company, LLC1,710,561$179.0M11.3%−575,000
Soleus Capital Management, L.P.1,704,318$178.3M6.1%+419,940
Bank Of America Corp /de/1,471,307$153.9M0.0%+756,978
Deerfield Management Company, L.P.1,451,014$151.8M1.9%−262,986
Morgan Stanley1,334,545$139.6M0.0%−11,170
Tang Capital Management LLC1,314,594$137.5M6.3%+264,594
Toronto Dominion Bank1,258,758$131.7M0.2%+376,000
Geode Capital Management, LLC1,111,662$116.3M0.0%+220,592
Wellington Management Group Llp906,595$94.8M0.0%+477,643
Goldman Sachs Group Inc870,449$91.1M0.0%+105,474
Point72 Asset Management, L.P.650,916$68.1M0.1%+370,592
Hood River Capital Management LLC628,411$65.7M0.5%New
Alliancebernstein L.P.530,922$60.6M0.0%+66,594
Fmr LLC548,983$57.4M0.0%+512,623
Apis Capital Advisors, LLC538,000$56.3M5.5%+23,000
Holocene Advisors, LP533,147$55.8M0.1%+163,168
UBS Group AG520,946$54.5M0.0%+300,783
Fuller & Thaler Asset Management, Inc.514,396$53.8M0.1%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Celcuity Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCelcuity Inc.1
  • CIK0001603454
  • Employer ID (EIN)82-28635664
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)8071 Services-Medical Laboratories1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address16305 36Th Avenue N, Suite 100, Minneapolis, MN 554461
  • Phone763-392-07671
  • Shares outstanding48,931,908 as of Aug 5, 202612
  • Public float$457.5M as of Jun 30, 20254
  • AuditorBoulay LLP, Minneapolis, Minnesota PCAOB ID 542; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMar 24, 20141
  • Filings540 in all: 4 (173), 8-K (89), SC 13G/A (28), 10-Q (27), D/A (21), 144 (18), 424B5 (15), 3 (12)1
    All 44 form types

    CORRESP (12), DEF 14A (11), SC 13G (11), SCHEDULE 13G/A (11), DEFA14A (10), S-8 (10), 10-K (9), D (9), UPLOAD (8), EFFECT (7), S-3 (6), SCHEDULE 13G (6), SCHEDULE 13D/A (5), ARS (4), PRE 14A (4), 8-K/A (3), FWP (3), S-1/A (3), 10-Q/A (2), 305B2 (2), 4/A (2), 424B3 (2), DRS/A (2), DRSLTR (2), S-3/A (2), 10-K/A (1), 424B4 (1), 8-A12B (1), CERTNAS (1), DRS (1), S-1 (1), S-1MEF (1), S-3ASR (1), SC 13D (1), SC 13D/A (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Mar 26, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Apr 2, 2026
    Latest 8-K (8-K) Oct 2, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.001 par value per shareCELCNasdaq

From the cover page of the 10-K filed Mar 26, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Celcuity Inc. names in Item 1A of its 10-K filed Mar 26, 2026: 47 risks under these headings, as written.4

  • Risks Relating to Our Business
  • We have not yet commercialized a pharmaceutical product, and we may never generate revenue or profit.
  • Our inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize our drug candidate, gedatolisib.
  • Future financing activities could dilute the percentage ownership of our stockholders and could cause our stock price to fall or could result in operating or other restrictions.
  • We are dependent on our ability to attract and retain key personnel.
  • Product liability claims may damage our reputation and, if insurance proves inadequate, these claims may harm our business.
  • We are expanding our development and regulatory capabilities and implementing sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
  • Changes to trade policy, including new or increased tariffs and changing import and export regulations, could have a material adverse effect on our business, results of operations and financial condition.
  • Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our debt obligations.
  • We may be unable to raise the funds necessary to repurchase the Notes for cash following a fundamental change or to pay any cash amounts due upon maturity, and our other indebtedness may limit our ability to repurchase the Notes or to pay any cash amounts due upon their maturity.
  • Provisions in the Indenture could delay or prevent an otherwise beneficial takeover of us.
  • Risks Related to Our Product Strategy
The other 37 risks
  • Our near-term revenue prospects depend on the success of our initial drug product, gedatolisib. If we are unable to successfully complete clinical development of, obtain regulatory approval for, or commercialize, gedatolisib, or if we experience delays in doing so, including supply chain interruptions, our business will be materially and adversely impacted.
  • We were not involved in the early development of gedatolisib; therefore, we are dependent on third parties having accurately generated, collected, interpreted and reported data from certain preclinical and clinical trials of gedatolisib.
  • We have not yet successfully completed any registrational clinical trials, and we may be unable to do so for any drug candidates we may develop.
  • The successful development of our products is highly uncertain.
  • If we encounter difficulties enrolling patients in any of our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • Interim, topline and preliminary data from our clinical studies that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Clinical development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
  • We face significant competition, and our operating results will suffer if we fail to compete effectively.
  • If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could face clinical trial delays; regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; and other adverse consequences.
  • Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information and personal data.
  • Public health matters may materially and adversely impact our business, including ongoing clinical trials.
  • Risks Related to Product Development and Product Regulation
  • Breakthrough Therapy Designation, Fast Track Designation, NDA submission via RTOR, and being awarded Priority Review from the FDA may not actually lead to a faster development or regulatory review or approval process.
  • Obtaining and maintaining FDA approval of our product candidates in the U.S. does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
  • Even if we receive initial regulatory approvals, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
  • Risks Related to Commercializing Our Products
  • Even if our products achieve requisite approvals, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
  • If we commercialize any product candidates, we will be subject to U.S. and foreign governmental regulations as well as private payor policies that mandate price controls or limitations on patient access to our products or establish prices paid by government entities or programs for our products. Our business and our future results could be adversely affected by changes in such regulations.
  • We may encounter difficulties in scaling production of, commercializing, marketing and distributing our products, including in hiring and retaining a qualified sales force.
  • Our business, operational and financial goals may not be attainable if the market opportunities for our products are smaller than we expect. Our internal research and third-party estimates may not accurately reflect the market opportunities for gedatolisib today or in the future.
  • Risks Related to Intellectual Property
  • We depend on intellectual property licensed from Pfizer for our lead product candidate, and termination of this license could result in the loss of significant rights, which would materially and adversely impact our business.
  • If we fail to comply with our obligations under our patent license with Pfizer, we could lose license rights that are important to our business.
  • We may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.
  • If we are not able to prevent disclosure of our trade secrets and other proprietary information, the value of our products could be significantly diminished.
  • We may be subject to claims by employees claiming ownership of what we regard as our own intellectual property.
  • If we are unable to obtain and maintain intellectual property protection for our product candidates, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize product candidates similar or identical to ours, and our ability to successfully commercialize our product candidates may be impaired.
  • Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
  • Any lawsuits relating to infringement of intellectual property rights necessary to defend ourselves or enforce our rights will be costly and time consuming and could be unsuccessful.
  • Risks Related to Our Reliance on Third Parties
  • We rely on third parties to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for, or commercialize, any potential product candidates.
  • Our reliance on third parties to formulate, manufacture and distribute our drug product exposes us to risks that may delay the development, regulatory approval and commercialization of our drug product or result in higher product and operational costs.
  • Performance issues or price increases by our shipping carriers could adversely affect our business, results of operations and financial condition, and harm our reputation and ability to provide our products on a timely basis.
  • Other Risks Related to Government Regulation for Our Business
  • Failure to comply with applicable U.S. data security and privacy regulations may increase our operational costs.
  • Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.
  • We will also need to expend a considerable amount of resources complying with other federal, state and foreign laws and regulations. If we are unable to comply or have not complied with such laws, we could face substantial penalties or other adverse actions.
  • Disruptions at the FDA and other government agencies from funding cuts, personnel losses, leadership changes, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development programs and develop and secure approval of our product candidates in a timely manner, which would negatively impact our business.
  • Risks Relating to Our Common Stock
  • Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
  • The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock or could subject us to securities litigation.
  • Future sales of shares of our common stock, including by us and significant stockholders, could negatively affect our stock price.

Legal proceedings

From time to time we may be involved in disputes or litigation relating to claims arising out of our operations. We are not currently a party to any legal proceedings that could reasonably be expected to have a material adverse effect on our business, financial condition and results of operations.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64